JOHNSON & JOHNSON PHARMACEUTICAL BUSINESSES HAVE NEW GROUP CHAIRMAN

Executive Summary

JOHNSON & JOHNSON PHARMACEUTICAL BUSINESSES HAVE NEW GROUP CHAIRMAN, Peter Tattle, 49, who assumed the new post on Oct. 8. Tattle will be responsible for U.S.-based Ortho Pharmaceutical, McNeil Pharmaceutical, R. W. Johnson Pharmaceutical Research Institute and Ortho Biotech units and the overseas Cilag group. J&J has more than a dozen company group chairmen. Tattle has been with J&J since joining the company as a sales representative for Ortho's Canadian operation in 1965. He was most recently responsible for Cilag as a VP of J&J International. Tattle will report to Vice Chairman Robert Wilson and will remain headquartered in New Brunswick, N.J. Former Ortho Pharmaceutical Chairman Jack Bowman moves to company group chairman in charge of Ortho Diagnostic Systems, Inc. He assumes responsibilities previously filled by Ronald Gelbman. The operations under Bowman's purview include Advanced Care Products, LifeScan and Immunobiology Research Institute. Bowman was recruited to J&J from the top pharmaceutical position at American Cyanamid/Lederle in mid-1987. The diagnostics area, a more developmental business segment at J&J than the established drug operations, will be a qnew field for Bowman. He is also maintaining touch with his previous pharmaceutical position through continuing responsibilities in the areas of licensing and joint ventures. Gelbman is assuming the company group chairman position for the Janssen Pharmaceutica companies worldwide. These companies formerly had reported directly to Wilson. Tattle, Bowman and Gelbman will report to Wilson. Gary Parlin, 50, succeeds Tattle in overseeing the Cilag companies with his promotion to company group chairman. Parlin, who reports to Tattle, also has "direct-line" responsibility for Ortho Biotech and the company's U.S. chemical manufacturing arm, Noramco, Inc. Parlin's Cilag responsibilities include companies in Europe, Latin America, Canada and Korea. A J&J employee since 1964, Parlin leaves the position of president of Ortho Pharmaceutical, which he held since 1983. He will transfer from Raritan to New Brunswick. Succeeding Parlin as Ortho president is former VP-sales and marketing Eric Milledge, 41, an 18-year J&J employee. Robert O'Neil assumes Milledge's position. O'Neil was formerly Ortho's VP-sales. In another promotion, Les Riley, 46, was named to fill the new position of president of Ortho's dermatological division. He previously was national sales manager and, most recently, head of the dermatological division.